NBC News @NBCNews
Experts say the price of insulin has remained high because of the combination of an increasingly complicated supply chain and “evergreening,” a process in which drug companies make incremental improvements to their products that can extend their patents. https://t.co/V8HJZ0fTvW — PolitiTweet.org